Functional outcome and quality of life after the surgical treatment for diffuse-type giant-cell tumour around the knee

被引:2
|
作者
van der Heijden, L. [1 ]
Mastboom, M. J. L. [1 ]
Dijkstra, P. D. S. [1 ]
van de Sande, M. A. J. [1 ]
机构
[1] Leiden Univ, Med Ctr, Dept Orthopaed Surg, NL-2300 RC Leiden, Netherlands
来源
BONE & JOINT JOURNAL | 2014年 / 96B卷 / 08期
关键词
PIGMENTED-VILLONODULAR-SYNOVITIS; ARTHROSCOPIC TREATMENT; TENDON SHEATH; SYNOVECTOMY; SURGERY; RECURRENCE; MANAGEMENT; YTTRIUM-90;
D O I
10.1302/0301-620X.9688
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
We retrospectively reviewed 30 patients with a diffuse-type giant-cell tumour (Dt-GCT) (previously known as pigmented villonodular synovitis) around the knee in order to assess the influence of the type of surgery on the functional outcome and quality of life (QOL). Between 1980 and 2001, 15 of these tumours had been treated primarily at our tertiary referral centre and 15 had been referred from elsewhere with recurrent lesions. The mean follow-up was 64 months (24 to 393). Functional outcome and QOL were assessed with range of movement and the Knee injury and Osteoarthritis Outcome Score (KOOS), the Musculoskeletal Tumour Society (MSTS) score, the Toronto Extremity Salvage Score (TESS) and the SF-36 questionnaire. There was recurrence in four of 14 patients treated initially by open synovectomy. Local control was achieved after a second operation in 13 of 14 (93%). Recurrence occurred in 15 of 16 patients treated initially by arthroscopic synovectomy. These patients underwent a mean of 1.8 arthroscopies (one to eight) before open synovectomy. This achieved local control in 8 of 15 (53%) after the first synovectomy and in 12 of 15 (80%) after two. The functional outcome and QOL of patients who had undergone primary arthroscopic synovectomy and its attendant subsequent surgical procedures were compared with those who had had a primary open synovectomy using the following measures: range of movement (114 versus 127 degrees; p = 0.03); KOOS (48 versus 71; p = 0.003); MSTS (19 versus 24; p = 0.02); TESS (75 versus 86; p = 0.03); and SF-36 (62 versus 80; p = 0.01). Those who had undergone open synovectomy needed fewer subsequent operations. Most patients who had been referred with a recurrence had undergone an initial arthroscopic synovectomy followed by multiple further synovectomies. At the final follow-up of eight years (2 to 32), these patients had impaired function and QOL compared with those who had undergone open synovectomy initially. We conclude that the natural history of Dt-GCT in patients who are treated by arthroscopic synovectomy has an unfavourable outcome, and that primary open synovectomy should be undertaken to prevent recurrence or residual disease.
引用
收藏
页码:1111 / 1118
页数:8
相关论文
共 50 条
  • [1] Results of the surgical treatment of diffuse pigmented villonodular synovitis (diffuse-type tenosynovial giant-cell tumor) of the knee
    Herasymenko, S., I
    Kostohryz, O. A.
    Kostohryz, Yu O.
    Babko, A. M.
    Maiko, V. M.
    ZAPOROZHYE MEDICAL JOURNAL, 2021, 23 (05) : 656 - 663
  • [2] Inconclusive benefit of adjuvant 90Yttrium hydroxyapatite to radiosynovectomy for diffuse-type tenosynovial giant-cell tumour of the knee
    Gortzak, Y.
    Vitenberg, M.
    Rutenberg, T. Frenkel
    Kollender, Y.
    Dadia, S.
    Sternheim, A.
    Morag, G.
    Farkash, U.
    Rath, E.
    Kramer, M.
    Drexler, M.
    BONE & JOINT JOURNAL, 2018, 100B (07): : 984 - 988
  • [3] MRI of diffuse-type tenosynovial giant cell tumour in the knee: a guide for diagnosis and treatment response assessment
    Geert Spierenburg
    Carlos Suevos Ballesteros
    Berend C. Stoel
    Ana Navas Cañete
    Hans Gelderblom
    Michiel A. J. van de Sande
    Kirsten van Langevelde
    Insights into Imaging, 14
  • [4] MRI of diffuse-type tenosynovial giant cell tumour in the knee: a guide for diagnosis and treatment response assessment
    Spierenburg, Geert
    Suevos Ballesteros, Carlos
    Stoel, Berend C.
    Navas Canete, Ana
    Gelderblom, Hans
    van de Sande, Michiel A. J.
    van Langevelde, Kirsten
    INSIGHTS INTO IMAGING, 2023, 14 (01)
  • [5] What Are the Recurrence Rates, Complications, and Functional Outcomes After Multiportal Arthroscopic Synovectomy for Patients With Knee Diffuse-type Tenosynovial Giant-cell Tumors?
    Yao, Lei
    Li, Yinghao
    Li, Tao
    Fu, Weili
    Chen, Gang
    Li, Qi
    Tang, Xin
    Li, Jian
    Xiong, Yan
    CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2024, 482 (07) : 1218 - 1229
  • [6] Diffuse-type tenosynovial giant cell tumour: Current treatment concepts and future perspectives
    Staals, Eric L.
    Ferrari, Stefano
    Donati, Davide M.
    Palmerini, Emanuela
    EUROPEAN JOURNAL OF CANCER, 2016, 63 : 34 - 40
  • [7] Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study
    Mastboom, Monique J. L.
    Palmerini, Emanuela
    Verspoor, Floortje G. M.
    Rueten-Budde, Anja J.
    Stacchiotti, Silvia
    Staals, Eric L.
    Schaap, Gerard R.
    Jutte, Paul C.
    Aston, Will
    Gelderblom, Hans
    Leithner, Andreas
    Dammerer, Dietmar
    Takeuchi, Akihiko
    Thio, Quirina
    Niu, Xiaohui
    Wunder, Jay S.
    van de Sande, Michiel A. J.
    LANCET ONCOLOGY, 2019, 20 (06): : 877 - 886
  • [8] Giant-cell tumour of the knee -: The condition of the cartilage after treatment by curettage and cementing
    von Steyern, F. Vult
    Kristiansson, I.
    Jonsson, K.
    Mannfolk, P.
    Heinegard, D.
    Rydholm, A.
    JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME, 2007, 89B (03): : 361 - 365
  • [9] Diffuse-type giant cell tumour of the tendon sheath of the proximal forearm
    Kandamany, N.
    Mahaffey, P. J.
    JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY, 2009, 62 (04): : 556 - 557
  • [10] CORR Insights®: What Are the Recurrence Rates, Complications, and Functional Outcomes After Multiportal Arthroscopic Synovectomy for Patients With Knee Diffuse-type Tenosynovial Giant-cell Tumors?
    Bus, Michael
    CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2024, 482 (07) : 1230 - 1231